Sec Form 4 Filing - Kreger James @ CRH Medical Corp - 2021-04-22

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Kreger James 2. Issuer Name and Ticker or Trading Symbol CRH Medical Corp [ CRHM] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President (Last) (First) (Middle) 3717 MANOR BROOK CT. NE 3. Date of Earliest Transaction (MM/DD/YY) 04/22/2021 (Street) ATLANTA, GA30319 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares ( 1 ) 04/22/2021 D 76,088 D $ 4 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Share Units ( 2 ) 04/22/2021 D 12,500 ( 3 ) ( 4 ) Common Shares 12,500 ( 3 ) 0 D Restricted Share Units ( 2 ) 04/22/2021 D 20,000 ( 3 ) 12/28/2020 Common Shares 20,000 $ 4 0 D Restricted Share Units ( 2 ) 04/22/2021 D 34,000 ( 3 ) ( 5 ) Common Shares 34,000 ( 3 ) 0 D Restricted Share Units ( 2 ) 04/22/2021 D 250,000 ( 3 ) 07/11/2026 Common Shares 250,000 $ 4 0 D Restricted Share Units ( 2 ) 04/22/2021 D 50,000 ( 3 ) ( 6 ) Common Shares 50,000 ( 3 ) 0 D Restricted Share Units ( 2 ) 04/22/2021 D 30,000 ( 3 ) ( 7 ) Common Shares 30,000 ( 3 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Kreger James 3717 MANOR BROOK CT. NE ATLANTA, GA30319 President Signatures /s/ Richard Bear, Attorney-in-fact for James Kreger 04/27/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Pursuant to the Arrangement Agreement, dated as of February 6, 2021 (as amended, the "Arrangement Agreement"), by and among CRH Medical Corporation ("CRH"), WELL Health Technologies Corp. ("WELL"), WELL Health Acquisition Corp., a wholly owned subsidiary of WELL, and 1286392 B.C. Ltd, a wholly owned subsidiary of WELL, at 4:30 p.m. Eastern Time (the "Effective Time") on April 22, 2021 each common share of CRH (each, a "CRH share") issued and outstanding immediately before the Effective Time was transferred to a subsidiary of WELL, and the holders thereof became entitled to receive US$4.00 in cash, without interest and less any applicable withholding taxes (the "Share Consideration"), for each CRH share then held. ( 2 )Each CRH RSU represented a contingent right to receive one CRH share. ( 3 )All options to acquire CRH shares ("CRH options") and share units with respect to CRH shares ("CRH RSUs") outstanding immediately prior to the Effective Time were exchanged for either a cash payment equal to Share Consideration (less the applicable exercise price in respect of CRH options) or replacement options or restricted stock units with respect to WELL common shares, in accordance with the terms of the Arrangement Agreement and the plan of arrangement subject to the same vesting schedule as applied to the CRH RSUs. ( 4 )By their terms, the CRH RSUs were scheduled to vest 50% on the second year anniversary of the grant date of December 7, 2017, 25% on the third year anniversary and the final 25% on the expiration date of December 7, 2021. ( 5 )By their terms, the CRH RSUs were scheduled to vest 25% on each of the first four annual anniversaries of the grant date of December 14, 2020. ( 6 )By their terms, the CRH RSUs were scheduled to vest 50% on the second annual anniversary of the grant date of June 30, 2019 and then 25% on each of the third and fourth anniversaries of the grant date. ( 7 )By their terms, the CRH RSUs were scheduled to vest 50% on the second year anniversary of the grant date of December 23, 2019, 25% on the third year anniversary of the grant date and the final 25% on the expiration date of December 23, 2029.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.